Publication | Open Access

Sandostatin, a new analogue of somatostatin, reduces the metabolic changes induced by the nocturnal interruption of continuous subcutaneous insulin infusion in Type 1 (insulin-dependent) diabetic patients

Metabolic SyndromeType 1Diabetes ManagementNew AnalogueInsulin ManagementPhysiologyPharmacologyDiabetesNocturnal InterruptionDiabetes MellitusInsulin DeliveryEndocrinologyMedicineInsulin SignalingHealth Sciences